Table 4.
Male
|
Female
|
|
OR (95%CI, P value)
|
OR (95%CI, P value)
|
|
|
Non-NAFLD (n = 2658) |
|
Unadjusted | 0.635 | 0.770 |
(0.548-0.736, < 0.001) | (0.682-0.870, < 0.001) | |
Model 1 | 0.403 | 0.581 |
(0.221-0.735, 0.003) | (0.344-0.981, 0.042) | |
Model 2 | 0.455 | 0.807 |
(0.246-0.842, 0.012) | (0.463-1.409, 0.452) | |
Model 3 | 0.330 | 0.800 |
(0.157-0.694, 0.003) | (0.416-1.537, 0.503) | |
NAFLD (n = 1311) | ||
Unadjusted | 0.789 | 0.845 |
(0.650-0.956, 0.016) | (0.739-0.966, 0.014) | |
Model 1 | 1.259 | 0.508 |
(0.542-2.924, 0.592) | (0.265-0.975, 0.042) | |
Model 2 | 1.954 | 0.710 |
(0.788-4.851, 0.148) | (0.355-1.418, 0.332) | |
Model 3 | 1.328 | 1.106 |
(0.435-4.055, 0.619) | (0.485-2.523, 0.810) |
Model 1: Adjusted for age, cigarette smoking, diabetes family history, FM, FM × ASM% quartiles, and obesity. Model 2: Adjusted for covariates in Model 1 plus SBP, TG, and HDL-C. Model 3: Adjusted for covariates in Model 3 plus HOMA-IR. OR: Odds ratio; FM: Fat mass; ASM: Appendicular skeletal muscle mass; SBP: Systolic blood pressure; TG: Triglycerides; HDL-C: High-density lipoprotein-cholesterol; HOMA-IR: Homeostasis model assessment for insulin resistance.